Search

17 Sep 2017: Phage display and kinetic selection of antibodies thatspecifically inhibit amyloid self-replicationAnna Munkea,1, Jonas Perssona,2, Tanja Weifferta, Erwin De Genstb,3, Georg Meislb, Paolo Arosiob,4, Anna Carnerupc,Christopher M. Dobsonb, Michele

47:03","modified_gmt":"2017-07-17T09:47:03","slug":"human-antibodies-developed-for-treatment-of-lupus-and-anthrax","status":"publish","type":"post","link":"https://www2.mrc-lmb.cam.ac.uk/ ... have recently emerged as promising new drug candidates to

31 Jul 2009: If approved, belimumab would become the first new drug treatment for lupus in 50 years. ... In a 52-week Phase 3 clinical study announced on July 20, 2009, patients with active systemic lupus erythematosus taking belimumab showed statistically

13 Sep 2021: Similarly, whilst the management of lupus has progressed enormously in the last 10 years, there are patients who do not respond to the most widely prescribed drugs and addressing this major ... disease. For example we breed mice that have been

30 Apr 2024: To bring these life changing medicines to patients takes many years of research and requires demonstration that these treatments are effective and safe. ... This information also allows us evaluate the doses that we need to deliver to be effective in

29 Apr 2024: Other autoimmune diseases such as lupus (SLE) can have devastating effects on patients lives, including debilitating symptoms which impact their ability to work. ... Current treatment options are not effective in treating all patients, and many have

19 May 2024: Patients will include people with autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, psoriasis, and multiple sclerosis, as well as immunodeficient patients, to help understand the immune response and progression

19 May 2024: Patients will include people with autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, psoriasis, and multiple sclerosis, as well as immunodeficient patients, to help understand the immune response and progression

Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients. ... An audit of recording cardiovascular risk factors in patients with rheumatoid arthritis and systemic lupus erythematosus in

{"id":4728,"date":"2014-01-13T15:04:42","date_gmt":"2014-01-13T15:04:42","guid":{"rendered":"http://cscs30.medschl.cam.ac.uk/ciddrg/?page_id=4728"},"modified":"2023-05-04T19:21:15","modified_gmt":"2023-05-04T18:21:15","slug":"publications","status":"